HPTN 084 Update: Long-Acting Injectable CAB vs Daily Oral TDF/FTC for HIV PrEP in Cisgender Women

July 29-August 2, 2022; Montreal, Quebec
An additional 1 year of unblinded follow-up of the HPTN 084 study continues to support superiority of long-acting injectable CAB vs daily oral TDF/FTC in reducing incident HIV infection among cisgender women at high risk.
Format: Microsoft PowerPoint (.ppt)
File Size: 298 KB
Released: August 3, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences, Inc.
ViiV Healthcare

Related Content

Dr William R. Short: key considerations for the use of long-acting cabotegravir and rilpivirine in pregnancy, from Clinical Care Options (CCO)

William R. Short, MD, MPH, AAHIVS Released: September 28, 2022

Expert selections of important HIV data from AIDS 2022, including current and investigational strategies for prevention, ART, comorbidities, and cure

Joseph J. Eron, Jr., MD Jeffrey Kwong, DNP, MPH, FAANP, FAAN Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP David A. Wohl, MD Released: September 23, 2022

Expert selections of important HIV data from AIDS 2022, including current and investigational strategies for prevention, ART, and comorbidities

Jeffrey Kwong, DNP, MPH, FAANP, FAAN Released: September 23, 2022

An expert panel of healthcare professionals and patient advocates discuss barriers faced by aging patients with HIV, from Clinical Care Options (CCO)

Jonathan Appelbaum, MD, FACP, AAHIVS
Program Director
Lydia Mungherera, MBChB Cristina Mussini, MD Dorothy Onyango Melanie Reese Marc Thompson
Released: September 23, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings